Best Warren Buffett Stocks To Buy Right Now

In this segment of The Motley Fool's everything-financials show,�Where the Money Is, banking analysts Matt Koppenheffer and David Hanson discuss the recent announcement of PacWest Bancorp's (NASDAQ: PACW  ) intention to buy CapitalSource (NYSE: CSE  ) .

David tells investors why this merger makes a lot of sense on paper but may not be a signal that the bank-M&A floodgates are set to open.

While opportunity may seem abundant with smaller bank stocks, many investors are still terrified about investing in big banking stocks after the crash, but the sector has one notable stand-out. In a sea of mismanaged and dangerous peers, it rises above as "The Only Big Bank Built to Last." You can uncover the top pick that Warren Buffett loves in The Motley Fool's�new report. It's free, so click here to access it now.

You can follow�David�and�Matt�on Twitter.

Best Warren Buffett Stocks To Buy Right Now: ONYX Pharmaceuticals Inc.(ONXX)

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. The company, through its collaboration agreement with Bayer HealthCare Pharmaceuticals, Inc., develops and markets Nexavar (sorafenib) tablet, a multiple kinase inhibitor for the treatment of liver cancer and advanced kidney cancer. It is also conducting Phase III clinical trial on Nexavar for the treatment of kidney, liver, lung, thyroid, breast, and non-small cell lung cancers; clinical trials on carfilzomib, a proteasome inhibitor for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors; and Phase Ib/II clinical trial on Oprozomib, an oral proteasome inhibitor. In addition, Onyx Pharmaceuticals, Inc. is developing ONX 0914, an immunoproteasome inhibitor, which is in preclinical stage for the treatment of autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease, and lupus. Further, the company, through its collaboration agreement with Bayer HealthCare Pharmaceuticals, Inc., is conducting clinical trials on Regorafenib, a multi-kinase inhibitor to treat metastatic colorectal cancer and gastrointestinal stromal tumors. It has a collaboration agreement with Warner-Lambert Company to discover and commercialize small molecule drugs that restore control of or intervene in the misregulated cell cycle in tumor cells. The company also has development and license agreements with BTG International Limited for the development and commercialization of ONX 0801, a novel targeted oncology compound; and Ono Pharmaceutical Co., Ltd. to develop and commercialize carfilzomib and Oprozomib for oncology indications in Japan. Onyx Pharmaceuticals, Inc. was founded in 1992 and is headquartered in South San Francisco, California.

Advisors' Opinion:

• [By Jon C. Ogg]

  Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Under Armour Inc. (NYSE: UA) may seem to have little to nothing in common on the surface. Questcor is in the pharmaceutical business, while Under Armour is the sports apparel and casual wear business. The world has now seen that Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) is being acquired for some $10.4 billion. The commonality between Questcor and Under Armour is that they were featured on the same recent high growth list of public companies expected to double their revenues over the next two to four years.

• [By Keith Speights]

  Nothing like being wanted
  Onyx Pharmaceuticals (NASDAQ: ONXX  ) experienced the thrill of being wanted this week. Shares soared nearly 57% this week after word leaked last weekend that Amgen (NASDAQ: AMGN  ) offered to buy the company for $120 per share.

• [By Alex Planes]

  Palboclib, a treatment for breast cancer, which Pfizer licenses from Onyx Pharmaceuticals (NASDAQ: ONXX  ) recently received breakthrough therapy designation status from the Food and Drug Administration this year. �On the other hand, Pfizer's new chronic myeloid leukemia drug Bosulif has been rejected by the U.K.'s cost agency National Institute for Health and Clinical Excellence. You win some, you lose some.

• [By Keith Speights]

  Also, more studies including Revlimid in first-line treatment of multiple myeloma are likely on the way. In April, results from a phase 1/2 trial with Onyx Pharmaceuticals' (NASDAQ: ONXX  ) Kyprolis in combination with Revlimid and low-dose dexamethasone� showed promising results. Onyx received Food and Drug Administration approval for Kyprolis as a third-line treatment for multiple myeloma in July 2012.�Kyprolis is technically a rival to Celgene's Pomalyst, but there's room for both drugs to be successful.

Best Warren Buffett Stocks To Buy Right Now: Alcoa Inc.(AA)

Alcoa, Inc. engages in the production and management of primary aluminum, fabricated aluminum, and alumina. The company operates in four segments: Alumina, Primary Metals, Flat-Rolled Products, and Engineered Products and Solutions. The Alumina segment engages in mining of bauxite, which is then refined into alumina. The Primary Metals segment produces aluminum. The Flat-Rolled Products segment engages in the production and sale of aluminum plate, sheet, and foil. The Engineered Products and Solutions segment produces and sells titanium, aluminum, and super alloy investment castings, hard alloy extrusions, forgings and fasteners, aluminum wheels, integrated aluminum structural systems, and architectural extrusions. Its products are used in aircraft, automobiles, commercial transportation, packaging, building and construction, oil and gas, defense, consumer electronics, and industrial applications. The company holds interests in bauxite mining activities. The company has op erations primarily in the United States, Australia, Spain, Brazil, the Netherlands, Norway, France, the Russian Federation, Hungary, Italy, the United Kingdom, China, and Germany. Alcoa, Inc. was founded in 1888 and is based in New York, New York.

Advisors' Opinion:

• [By Monica Gerson]

  Alcoa (NYSE: AA) is projected to post its Q3 earnings at $0.06 per share on revenue of $5.63 billion.

  EXFO (NASDAQ: EXFO) is expected to post its Q4 earnings at $0.05 per share on revenue of $60.94 million.

• [By Eddie Staley]

  Top Headline
  Alcoa (NYSE: AA) reported a loss in the fourth quarter on Thursday. Alcoa posted a quarterly loss of $2.34 billion, or $2.19 per share, versus a year-ago profit of $242 million, or $0.21 per share. Excluding one-time items, it earned $0.04 per share. Its revenue dropped 5% to $5.59 billion. However, analysts were expecting earnings of $0.06 per share on revenue of $5.36 billion.

• [By Dan Caplinger]

  Offsetting the impact
  Still, sometimes, good and bad performances cancel each other out. The smallest stock in the Dow, Alcoa (NYSE: AA  ) , was also its worst performer, losing 5% since last June. But since its shares fetch only about $8, that loss barely affected the Dow at all. In an equal-weight Dow, however, it would have just as big an influence as any other stock.

• [By Matt Thalman]

  Alcoa (NYSE: AA  ) �was also hurt by falling commodity prices. While the aluminum manufacturer saw its share price fall 1.2% today, the price of aluminum fell by 1.19%.�Growing concerns that the global economy is slowing, which would likely weaken demand, and a growing supply of the metal, continue to put downward pressure on the per ton price of aluminum. Although the company recently beat earnings estimates, it missed on revenue, which is a sign that the management team is running a tight ship. But, if the price of aluminum continues to decline, there may not be anything management can do to keep the company profitable.

Top Logistics Stocks To Own Right Now: Oceaneering International Inc.(OII)

Oceaneering International, Inc., together with its subsidiaries, provides engineered products and services primarily to the offshore oil and gas industry with a focus on deepwater applications. The company?s Remotely Operated Vehicles segment provides submersible vehicles operated from the surface to support offshore oil and gas exploration, production, and construction activities. Its Subsea Products segment supplies various built-to-order specialty subsea hardware products. The company?s Subsea Projects segment provides multiservice vessels, oilfield diving, and support vessel operations, which are used primarily in inspection, repair, and maintenance and installation activities; and mobile offshore production systems. Its Inspection segment offers customers with a range of third-party inspection services to satisfy contractual structural specifications, internal safety standards, and regulatory requirements. The company?s Advanced Technologies segment offers project management, and engineering services and equipment for applications in non-oilfield markets. Oceaneering International, Inc. also serves defense and aerospace industries. It operates primarily in west Africa, Norway, the United Kingdom, Asia, Australia, Brazil, and the United States. The company was founded in 1965 and is based in Houston, Texas.

Advisors' Opinion:

• [By Chris Hill]

  Gold continues its decline. Citigroup (NYSE: C  ) gets a boost from its investment banking business. Netflix� (NASDAQ: NFLX  ) gets a boost from analyst upgrades. And Oceaneering International (NYSE: OII  ) slips on falling oil prices. In this installment of Investor Beat, our analysts discuss four stocks making moves.

• [By Taylor Muckerman and Joel South]

  Oceaneering International (NYSE: OII  ) is a pure play on the deepwater space with its remotely operated vehicles and other subsea equipment. Both it and its similarly priced peer, FMC Technologies (NYSE: FTI  ) , compete for headlines tomorrow during earnings season. While guidance hasn't changed since last week, the market will almost certainly be looking for results on the high side or even expectation-beating numbers. What do Motley Fool analysts Joel South and Taylor Muckerman expect from these companies tomorrow?

• [By Jeremy Bowman]

  What: Shares of Oceaneering International (NYSE: OII  ) were rising with the tide today, gaining as much as 10% after delivering a strong quarter and a healthy dividend hike.

Best Warren Buffett Stocks To Buy Right Now: Bluforest Inc (BLUF)

Bluforest Inc., formerly Greenwood Gold Resources, Inc., incorporated on March 26, 2008, is a carbon offset credit trading company with land assets in South America. Global Environmental Investments Limited (GEIL) sold all of the rights and interests held by GEIL pursuant to the Acquisition Agreement, on March 30, 2012, to the Company regarding the Property, which consists of approximately 105,000 hectares. It consists of 100% of GEIL�� rights, title and interests in and to the timber, minerals, substances and the rights to receive from the Property, and 100% of the right, title and interests of GEIL in all existing oil, gas and/or mineral unitization, pooling and/or communization agreements, declarations, and/or orders and the properties covered or included in the units, which relate to the Property.

The Property consists of 100% of the right, title and interests of GEIL in all existing and agreements, including sales and sales related contracts, operating agreements and other agreements and contracts, which relate to Fundacion Nelson Velasco Aguirre (NVA), the Property or which relate to the exploration, development, operation or maintenance of the Property or the treatment, storage, transaction or marketing of production from or allocated to the Property. The 105,000 hectares also consists of 100% of the right, title and interests of GEIL in and to all materials, supplies, machinery, equipment, improvements, and other personal property and fixtures relating to the Property, and all wells, wellhead equipment, pumping units, flow lines, tanks, buildings, injection facilities, salt water disposal facilities, compression facilities, gathering systems and other equipment, all easements, rights-of-way, surface leases and other surface rights, all permits and licenses and all other appurtenances, used or held for use in connection with or related to the exploration, development, operation or maintenance of any of the Property.

Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks BluForest Inc (OTCMKTS: BLUF), Dephasium Corp (OTCMKTS: DPHS) and IceWEB, Inc (OTCBB: IWEB) have been getting some attention for at least a few weeks now thanks to paid for promotional activity. Of course, there is nothing wrong with properly disclosed stock promotions, but one of these stocks also has a former shareholder who has filed a civil action against it alleging there is an illegal ��ump and dump��scheme going on. So what�� the whole story and more importantly, what will happen with these small cap stocks when the well from promoters eventually goes dry? Here is a closer look and a quick reality check:

• [By Peter Graham]

  Small cap green stocks Eco-Tek Group Inc (OTCMKTS: ETEK) and BluForest Inc (OTCMKTS: BLUF) have been getting some attention lately thanks to some green���as in paid for promotions. Of course, there is nothing wrong with properly disclosed promotions, but one of these stocks happens to be getting a considerable amount of attention as its been the subject of numerous transactions. With that in mind, will investors see some green with these green small cap stocks? Here is a quick reality check:�

• [By Peter Graham]

  What�� the Catch With Multi-Corp International Inc? According to various disclosures, no transactions have occurred to mention Multi-Corp International in various investment newsletters. Moreover, I am not seeing any recent news on the newswires about the company with the latest press release dating from late July about the posting of a blanket bond. However and as I noted in an earlier about BluForest Inc (OTCMKTS: BLUF), the company has been named in a Freedom of Information request with the SEC by George Sharp (of Pumps&Dumps.com) for all complaints filed against Jim Can. George apparently contends that Jim controls BluForest along with Multi-Corp International, but the former has recently won an injunction against the latter for ��lleged, completely false, defamatory claims and statements.��Otherwise, investors should be aware that Multi-Corp International�� most recent financials date from the end of September of last year ��meaning its investor beware until they get current.

Best Warren Buffett Stocks To Buy Right Now: Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp (SBS)

Companhia de Saneamento B sico do Estado de Sao Paulo - SABESP provides water and sewage services to residential, commercial, industrial, and governmental customers in the State of Sao Paulo. Its services comprise water supply, sanitary sewage services, urban rainwater management and drainage services, urban cleaning services, and solid waste management services, as well as related activities, including the planning, operation, maintenance, and commercialization of energy. As of December 31, 2010, it provided water services through 7.3 million water connections to approximately 23.6 million people; and sewage services through 5.7 million sewage connections to approximately 20 million people. The company was founded in 1954 and is headquartered in Sao Paulo, Brazil.

Advisors' Opinion:

• [By Carlton Delfeld]

  Companhia de Saneamento Basico do Estado de Sao Paulo (SBS) is commonly called SABESP. I like the stock for three reasons:

  First, the company has plenty of room to grow in Sao Paulo, other regions in Brazil, and even in neighboring countries. Sao Paulo has a population over 40 million and represents 30% of Brazil's total economic output.

Best Warren Buffett Stocks To Buy Right Now: Catamaran Corp (CTRX)

Catamaran Corporation (Catamaran), formerly SXC Health Solutions Corp., incorporated on June 27, 2007, is a provider of pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefit management industry. The Company�� product offerings and solutions combine a range of applications and PBM services designed to assist its customers in reducing the cost and managing the complexity of their prescription drug programs. The Company�� customers include organizations in the pharmaceutical supply chain, such as pharmacy benefit managers, managed care organizations, self-insured employer groups, unions, third party health care plan administrators, and state and federal government entities. In January 2012, the Company completed its acquisition of HealthTran LLC (HealthTran). On July 2, 2012, the Company acquired Catalyst Health Solutions, Inc. On October 1, 2013, the Company acquired RESTAT, LLC.

The Company�� PBM services, which are marketed under the Catamaran PBM brand, include electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail pharmacy claims management, specialty pharmacy claims management, Medicare Part D services, benefit design consultation, preferred drug management programs, drug review and analysis, consulting services, data access, and reporting and information analysis. The Company's PBM services include owning and operating a network of mail and specialty pharmacies. In addition, the Company is a national provider of drug benefits to its customers under the federal government�� Medicare Part D program. The Company�� HCIT solutions include RxCLAIM, an on-line transaction processing system that provides instant adjudication of prescription drug claims, RxMAX, the Company�� rebate management system, RxTRACK, the Company�� data warehouse and analysis system, Zynchros, the Company�� suite of on-demand formulary management tools, the Company�� pharmacy management system! for retail, chain, institutional and mail-order pharmacies, as well as a number of other software products for customers in the pharmaceutical supply chain. The Company�� HCIT solutions are available on a license basis with on-going maintenance and support or on a transaction fee basis using an application service provider (ASP) model.

PBM Services

The Company�� informedRx offering is a suite of customizable PBM services that provide an alternative to traditional PBM offerings typically employed by health plans, government agencies and employers. The Company provides a range of pharmacy spend management solutions and information technology capabilities to managed care organizations, self-insured employer groups, unions, third party health care plan administrators, and state and federal government entities. Formulary Administration provides support for customers��existing formularies and preferred drug lists or collaborate to create models supported by formulary predictive modeling and impact analysis. Pharmacist, physician and member-focused intervention protocols provide controls to drive generics, preferred drug products and appropriate use. Formularies are administered based on specific plan designs, or by enabling customers with the tools to maintain their own custom formularies online.

The Company specializes in applying data-driven insights to help customers understand the medical risk drivers within their population and take a strategic approach to plan design. The Company provides benefit design configuration and support to customers, in accordance with mutually developed processes. Benefit designs can be modified online, in real time, by the Company or by the customer�� staff. Pharmacy Network Management provides a range of retail network options, including supporting existing networks or assisting customers in developing networks that meet specific geographic access requirements, desired price discounts, or other service requirements. A national! retail n! etwork, which consists of pharmacies in all 50 states and in Puerto Rico, Guam and the Virgin Islands, provides access to the Company�� customers.

Drug Utilization Review (DUR) is pre-dispensing DUR edit checks are performed on an online, real-time basis between mail and retail pharmacies to encourage appropriate drug utilization, enhance member outcomes, and reduce drug costs. All prescriptions are checked for member eligibility and plan design features and are then compared against previous histories of prescriptions filled by the same pharmacy, by other participating retail network pharmacies and by the mail service pharmacy. Clinical Services and Consulting provides consultative and technical expertise to augment, develop, deploy, and support any additional clinical programs. Reporting and Information Analysis Solutions provides two levels of reporting: a reporting package (which includes a menu of reports), and an online analytical decision support tool, RxTRACK. The Company offers mail and specialty services to its PBM members, as well as other members of its pharmacy network. suite of Web-based services that enables customers to interact with the claims processing system using a standardized protocol in a secure environment. A member Website, RxPORTAL, invites members to learn more about their prescription benefit programs, medication histories, drug information and related industry news. RxPROVIDER PORTAL is a Web-based interface that allows pharmacists and physicians to obtain information from RxCLAIM on a member's plan to assist in providing more cost effective prescription medications.

Healthcare IT

The Company's HCIT offerings deliver applications on a license, ASP, or fee-for-service basis to customers who administer and manage pharmacy benefits. HCIT products and services serve a diversified group of payor customers that include health plans, federal, state and provincial government programs, pharmacy benefit managers, workers' compensation programs! , and lon! g-term and/or chronic care facility operators. In addition, SXC's technology serves as the engine for the Company's service PBM solutions.

Technology Products and Services

RxCLAIM is an on-line transaction processing system designed to provide instant on-line adjudication of third-party prescription drug claims at the point of service, including claims management, as well as payment and billing support and real-time functionality for updating benefit, price, member, provider and drug details. RxCLAIM is designed to provide the Company�� customers control by facilitating the real-time processing of pharmacy claims and payments against eligibility, plan benefits, formularies, price, drug utilization review, prior authorization, and rebates in addition to many other features.

Other products

Integrail Pathfinder PRO is a software application that enables a array of users to understand the impact of healthcare resource allocation and medical decision-making through the incorporation of risk prediction and episode profiling technologies. The application offers users an intuitive system for integrating disparate data sources to pinpoint variations in resource utilization and care. IntegrailRx features the ability to measure and predict both pharmacy and total risk using pharmacy claims. RxBUILDER is a Web-based interface for formulary creation and maintenance utilizing a Medi-Span based product file. RxPORTAL allows customers to interact with the patient's formulary and drug history in a secure environment allowing patients and health plans to access industry tools and up to date information. RxAUTH is a prior authorization (PA) management solution, which offers automating the PA process from end-to-end. RxAUTH is also available in a Web-based application. RxMAX is a rebate management system that is designed to assist health plans in managing their relationships with pharmaceutical manufacturers through contract management, record keeping, calculating market share! , and cre! ating billing details and summaries. Zynchros provides a suite of on-demand formulary management tools to help payors effectively manage their formulary programs, and to maintain Medicare Part D compliance in their programs. Enhanced Coordination of Benefits integrates external data sources with unique algorithms and eligibility data to identify beneficiaries with other coverage. This enables accurate identification of third party liability in real-time prior to the claim being paid.

Medicare Part D

The Company has offered an array of services to the Medicare marketplace, all compliant with Centers for Medicare and Medicaid Services (CMS) regulations. As a full-service PBM and a National Prescription Drug Plan, the Company supports a variety of Medicare Part D Plan Sponsors. The Company provides prescription benefit management support for Medicare Advantage Prescription Drug plans (MAPDs) and prescription drug plans (PDPs), including implementation of specific Medicare Part D plan designs, creation and maintenance of Medicare Part D formularies (including CMS submission), CMS reporting requirements and consultative, proactive account management.

The Company competes with Express Scripts, Inc., CVS/Caremark Corporation and OptumRx.

Advisors' Opinion:

• [By Brian Pacampara]

  Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health care IT services specialist Catamaran (NASDAQ: CTRX  ) has earned a coveted five-star ranking.

• [By Lee Jackson]

  Health Care: Catamaran Corp. (NASDAQ: CTRX) provides pharmacy benefit management services and health care information technology solutions to the health care benefits management industry in North America. Credit Suisse believes the company’s growth profile, potential upside to synergy targets from recent acquisitions, and the chance to expand into the large employer market should drive outperformance in shares. The target price for the stock is $64, and the consensus is posted higher at $68. Trading to either target represents a gain of almost 40%. Catamaran closed Tuesday at $46.85.

Best Warren Buffett Stocks To Buy Right Now: Exxon Mobil Corporation(XOM)

Exxon Mobil Corporation engages in the exploration and production of crude oil and natural gas, and manufacture of petroleum products, as well as transportation and sale of crude oil, natural gas, and petroleum products. The company manufactures and markets commodity petrochemicals, including olefins, aromatics, polyethylene and polypropylene plastics, and other specialty products. As of December 31, 2010, it operated 35,691 gross and 30,494 net operated wells. The company has operations in the United States, Canada/South America, Europe, Africa, Asia, and Australia/Oceania. Exxon Mobil Corporation was founded in 1870 and is based in Irving, Texas.

Advisors' Opinion:

• [By Matt DiLallo]

  What basically happened, and you can read the full story here, is that for seven months the wells, now owned by XTO, were producing gas but XTO wasn't getting paid for the gas. Now, Dominion owes XTO's new owner, ExxonMobil (NYSE: XOM  ) , a grand total of $3.4 million for the gas and just over $900,000 in interest. It can appeal the ruling, but it's probably not a large enough amount to fight over.

• [By Victor Selva]

  It is best suited for investors looking for diversification across sectors at a low cost. Let's see the fund麓s holding list:

  Apple Inc (AAPL) 3.21% Exxon Mobil Corp (XOM) 2.80% Google Inc (GOOG) 1.97% General Electric Co (GE) 1.80% Microsoft Corp (MSFT) 1.78% Johnson & Johnson (JNJ) 1.62% Chevron Corp (CVX) 1.52% Procter & Gamble Co (PG) 1.40% JPMorgan Chase & Co (JPM) 1.38% Wells Fargo & Co (WFC)1.38%

  Total Percentage of Top 10 Holdings: 18.86%

• [By Claudia Assis]

  Shares of Exxon Mobil Corp. (XOM) �fell 0.2%, while shares of Chevron Corp. (CVX) �were down 0.7%. ConocoPhillips (COP) �shares turned higher, however, ending up 0.1%.

• [By Aaron Levitt]

  With that said, the Oracle of Omaha�� latest major is buy is certainly a doozy in both the size and potential value. That huge purchase was major integrated oil stock Exxon Mobil (XOM).

Best Warren Buffett Stocks To Buy Right Now: Foundation Medicine Inc (FMI)

Foundation Medicine, Inc., incorporated on November 12, 2009, is a commercial-stage company. The Company is focused on fundamentally changing the way patients with cancer are treated. The Company�� platform includes methods and algorithms for analyzing tumor tissue samples across all types of cancer, as well as information aggregation and concise reporting capabilities. Its products provide genomic information about each patient�� individual cancer, enabling physicians to optimize treatments in clinical practice and enabling biopharmaceutical companies to develop targeted oncology therapies more effectively.

FoundationOne, its first clinical product, is, to its knowledge, the only commercially available comprehensive molecular information product designed for use in the routine care of patients with cancer. In addition, the Company is considered a non-contracting provider by commercial third-party payors because it has not entered into specific contracts to provide FoundationOne to their covered patients, and as a result it takes on primary responsibility for obtaining reimbursement on behalf of patients.

Advisors' Opinion:

• [By John Udovich]

  If you have not been watching the biotech sector lately, you should start paying attention as the sector along with small cap biotech stocks like Cell Therapeutics Inc (NASDAQ: CTIC), BIND Therapeutics Inc (NASDAQ: BIND) and TNI BioTech (OTCMKTS: TNIB) continue to produce a steady stream of good news for investors thanks to positive industry trends. Moreover, Ophthotech Corp (NASDAQ: OPHT), Foundation Medicine Inc (NASDAQ: FMI), Evoke Pharma and Fate Therapeutics Inc (NASDAQ: FATE) are this week's biotech IPOs that will no doubt be watched closely by Wall Street and industry observers in general. With that in mind, consider the following biotech news or recent articles about the industry and the small cap players in it:

• [By John Udovich]

  Yesterday, small cap biotech Acceleron Pharma Inc (NASDAQ: XLRN) rose 9.76%�plus shares are up 183.6% for retail investors since its September IPO, meaning its worth taking a closer look at the stock along with the performance of other biotech IPOs like BIND Therapeutics Inc (NASDAQ: BIND), Ophthotech Corp (NASDAQ: OPHT) and Foundation Medicine Inc (NASDAQ: FMI) which also debuted at the same time.

• [By Lisa Levin]

  Foundation Medicine (NASDAQ: FMI) shares tumbled 7.58% to reach a new 52-week low of $21.23. Foundation Medicine's trailing-twelve-month profit margin is -147.08%.

• [By Dan Caplinger]

  In the following video, Dan Caplinger, director of investment planning for The Motley Fool, looks at whether the IPO market is overheating once more. Dan points to some huge gains from recent IPOs, with FireEye (NASDAQ: FEYE  ) rising 80% in its first day while Rocket Fuel (NASDAQ: FUEL  ) and Foundation Medicine (NASDAQ: FMI  ) both posted gains of between 90% and 100%. Dan also highlights Sprouts Farmers Market� (NASDAQ: SFM  ) , which climbed a whopping 123% in its first day as a public company.

Best Warren Buffett Stocks To Buy Right Now: HCP Inc. (HCP)

HCP, Inc. is an independent hybrid real estate investment trust. The fund invests in real estate markets of the United States. It primarily invests in properties serving the healthcare industry including sectors of healthcare such as senior housing, life science, medical office, hospital and skilled nursing. The fund also invests in mezzanine loans and other debt instruments. It engages in acquisition, development, leasing, selling and managing of healthcare real estate and provides mortgage and other financing to healthcare providers. The fund benchmarks the performance of its portfolio against the S&P 500 Index, Berkshire Hathaway Index, and MSCI REIT Index. HCP, Inc. was formed in 1985 and is based in Long Beach, California with additional office in Nashville and San Francisco.

Advisors' Opinion:

• [By Ben Levisohn]

  My vote for the strangest drop of the week goes to HCP (HCP). The healthcare real-estate investment trust fell 6% to $39.05 after it fired its CEO without warning and insisted there was nothing behind it except desire for a different management style. Investors were not enthused.

• [By Roberto Pedone]

  You don't have to be an expert technical analyst to see what's going on in shares of health care REIT HCP (HCP). This stock is in stuck in a textbook downtrending channel. Fundamentally, there's a lot to like about this stock, but HCP is a good example of why it's never a good idea to chase yield; HCP may have a 5.29% annual dividend payout, but shares have lost more than that in the last month alone.

  HCP's price channel has provided traders with a high-probability range for shares since the middle of the year. Despite the last four attempts at pushing through trendline resistance, shares have been swatted down on each attempt. And while HCP has been turning higher in the last few sessions, investors should look at trendline resistance at $42 with a lot of skepticism. That's probably the worst possible time to be a buyer.

  Instead, it makes sense to sell near the trendline for a most efficient exit in HCP. Yes, trendlines do eventually break, but getting in now is a big mistake. After all "this time it's different" are probably the most expensive four words in the English language. As long as shares stay within that channel, sell the bounce.

• [By Dimitra DeFotis]

  Among real estate trusts:

  American Tower��(AMT),�the diversified �REIT, is the best performer in the index.�It was�up 4.6% after saying�Friday it will buy the parent of tower operator Global Tower Partners for $4.8 billion. HCP (HCP), a healthcare REIT, was�up 3.3%. Prologis (PLD) an industrial REIT, was�up 2.8%. Vornado Realty Trust (VNO) was�up 2.7%. Boston Properties (BXP), the office REIT, was�up 2.3%. Equity Residential (EQR), a residential REIT, was�up 2.4%. Ventas (VTR), a healthcare REIT, was�up 2%.